SUNPHARMA Q2 FY27 Earnings Call: Reaffirms High Single-Digit FY27 Growth, India Sales Jump 17.3%

SUNPHARMA held its Q2 FY27 earnings call on October 30, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Double-Digit Top Line, Margin Compression on Lenalidomide Base

• Consolidated sales of Rs.1,61,000 million — up 11.8% YoY vs Q2 FY 2025-2026; gross margin at 80.8%, higher YoY on better product mix and favorable currency tailwinds.
• EBITDA of Rs.47,439 million (+4.8% YoY) — margin at 29.3%, lower YoY as Q2 FY 2025-2026 had benefit from lenalidomide sales; adjusted for lenalidomide, EBITDA growth outpaced revenue growth.
• Reported net profit of Rs.19,885 million — adjusted net profit at Rs.31,620 million; EPS at Rs.8.3 per share; effective tax rate at 28.3% vs 24.7% in Q2 FY 2025-2026.
• Exceptional items — provision towards a litigation settlement and Organon-related acquisition costs; forex gain of Rs.785 million, lower than Q2 FY 2025-2026.
• H1 FY 2026-2027 sales of Rs.3,12,836 million (+11% YoY) — gross margin 80.6%; EBITDA Rs.91,615 million (+3.8% YoY) at 29.1% margin; adjusted net profit Rs.62,515 million.
• Net cash of US$3.3 billion — CFO Jayashree Satagopan cited the successful subscription of the company's debut NCD issue as underscoring its credit profile and investor confidence.

India Broad-Based Strength; US Down on Lenalidomide, EM Picks Up

• India formulation sales grew 17.3% YoY to Rs.55,523 million — 34.5% of consolidated sales; growth broad-based across all 12 major therapeutic areas, with 15 new products launched in India in Q2 FY 2026-2027.
• Sun Pharma volume growth of 6% vs IPM volume growth of 1.6% — per AVAX market data (Q2 FY 2026-2027); roughly 50-60% of India growth came from volume plus new launches, remainder from pricing; per PharmaTrack MAT September 2026, Sun is ranked number one with 8.6% share in the over-Rs.2,618 billion Indian pharmaceutical market, up from 8.3%.
• US sales of $455 million, down 8.2% YoY — largely due to lenalidomide erosion, but up 6.5% QoQ on five new generic launches; US accounted for 27% of consolidated sales.
• Emerging markets revenue of US$350 million, up 7.6% YoY — underlying CC growth of 7.4%; 20.7% of consolidated revenue; branded generics and innovative medicines (Ilumya in Romania and Brazil) drove growth; partner launched semaglutide generics in Brazil.
• Rest of world revenue of US$241 million — higher than the year-ago quarter; ~14.3% of consolidated revenue; management acknowledged ROW growth is currently lower than EM but declined standalone ROW guidance.
• Global innovative medicine sales of US$356 million (+6.9% YoY) — 21.1% of sales, driven by Ilumya, Sikuwa and Odumzo; Ilumya slowdown in the US was cited as a key reason behind slower growth in global innovative medicines.

Ilumya Execution Fixes Underway; PsA Launch and NCCN Catalysts

• Ilumya slowdown attributed to saturation plus execution — Richard Astore (CEO – North America) cited "a variety of things", including market saturation and execution shortfalls for which interventions are already in place; management expects actions plus the PsA launch to return Ilumya to "more typical growth patterns" over the next few quarters (H2 FY 2026-2027 onward).
• Ilumya PsA indication approved in the US — soft launch planned for November 2026 (Q3 FY 2026-2027) with full launch in following months; positioned as the only physician-administered IL-23 for PsA and the only HCP-administered product rheumatologists can dose quarterly; PsA launch expenses are built into the overall FY 2026-2027 budget.
• No product-specific guidance on Ilumya — Astore declined to size the franchise opportunity; only quantification offered: about one-third of psoriasis patients also have comorbid psoriatic arthritis.
• Ilumya LOE "not in the foreseeable future" — Astore noted the IL-23 class remains dominant among clinicians for psoriasis and Ilumya's HCP-administered model for patients requiring extra care is a unique attribute; management sees "plenty of opportunity" in the US, particularly the Medicare channel.
• Unloxit elevated to category 2A preferred recommendation in NCCN guidelines — for advanced CSCC; long-term data presented at a leading European scientific conference showed complete responses in 34% of locally advanced and 17-21% of metastatic patients, with very low high-grade immune-related adverse events.
• Lexelvi new data shows durability — physicians report speed of response playing out in patients; management did not commit to a specific timeline for meaningful contribution from recent US specialty launches (Lexel B over a year old, Sunluxe ~9 months).

Five Novel Entities in Clinic; R&D Spend Tracking Below Intended Levels

• Q2 FY 2026-2027 R&D spend of Rs.7,784 million (4.8% of sales) — innovative R&D accounted for 32.4% of total R&D spend; management noted spend is tracking lower than intended but expects H2 FY 2026-2027 to catch up.
• 6 to 7% full-year R&D guidance for FY 2026-2027 — Chairman Dilip Shanghvi said spend is expected to significantly ramp up in Q3 FY 2026-2027 and the company should be able to meet the overall guidance; no product- or market-level breakdown of the step-up was provided.
• 5 novel entities in clinical development — Shanghvi cautioned that commercial potential carries inherent R&D uncertainty, since realized market share depends on final clinical outcomes; the company invests only where it expects a decent risk-adjusted return on investment.
• Lerodalcibep (PCSK9 inhibitor) flagged as the key catalyst — per management, the product that can be the next to materially alter the specialty growth trajectory over the next 2 to 3 years, scoped ex-US and ex-China; European EMA approval already in hand, with pricing and reimbursement dossier submissions typically taking 6-12 months per market; product currently in pre-launch phase.
• Nidlegy filed, approval awaited — Shanghvi did not provide an approval timeline; positioning vs checkpoint inhibitors will depend on the labels both products receive; Nidlegy is licensed only for Europe and a few other markets and will not be a comparable opportunity to Unlocset, which is a global product with launches planned gradually as approvals come.
• Semaglutide India: FY 2026-2027 is the first year of commercialization — management did not guide on FY 2027-2028 growth, noting GLP-1 drugs are performing "phenomenally well" worldwide and that any new product in India takes 3-4 years to build; pricing decisions in Brazil/South Africa rest with the partner and were not disclosed.

On Track for Q4 FY 2026-2027 Close; Exceptional Costs to Continue

• Organon acquisition on track to close in Q4 FY 2026-2027 — integration planning progressing across functions and workstreams in line with plan; regulatory approvals secured in a majority of regions with remaining jurisdictions tracking on schedule; management stated early 2027 close, subject to remaining customary closing conditions.
• Acquisition-related costs will continue until day one of deal close — recorded in P&L exceptional expense in Q2 FY 2026-2027; additional exceptional expenses will be incurred in Q3 FY 2026-2027 and through the transaction's progression, some of which could be back-ended; full estimate available only when the transaction closes in Q4 FY27 (FY 2026-2027).
• Deal financing rate being finalized — CFO Jayashree Satagopan said it should be "more or less in line with the current borrowing cost of Organon"; no specific rate disclosed; goodwill attribution "too early" to comment and will be determined per accounting standards as of the acquisition date.
• NCDs are not Organon financing — the FY 2026-2027 NCDs (raised at 8% and 8.2% per exchange disclosures cited by the analyst) are rupee-denominated normal financing to repay current borrowings, whereas Organon transaction financing is mostly dollar and euro; the CFO confirmed Organon's 7.875% weighted average cost of debt (per its latest SEC filing) is the relevant reference.
• No questions taken on Organon's business performance — Organon remains a separate public listed company.

FY27 Guidance Reaffirmed; Assam Recall and Tariff Agreement in Focus

• High single-digit top-line growth guidance for FY27 reaffirmed — despite H1 FY27 top-line growth tracking around double-digit (analyst's observation), MD Kirti Ganorkar said the company will stick to the guidance given at the beginning of the year.
• India volume sustainability not guided — Ganorkar said it is "very difficult to predict" whether 6% volume growth continues in Q3 FY 2026-2027 or the following two quarters; management attributed growth to cumulative efforts (brand building, field force expansion, new launches) and did not quantify volume growth excluding semaglutide.
• Assam plant: voluntary recall of 11 ophthalmology products — management clarified it voluntarily recalled the products and voluntarily initiated a temporary cessation of manufacturing, keeping the Indian regulator informed; Chairman Dilip Shanghvi declined to comment on a media report that the Indian drug regulator asked the company to discontinue ophthalmic production at the plant; remedial action is underway with operations to be put in place "shortly"; no material adverse impact on numbers was quantified.
• US government pricing agreement — Sun Pharma will extend most favored nation pricing to state Medicaid programs; the agreement delays Section 232 tariffs on innovative products for over 2 years and exempts Sun Pharma from the GLOBE and GUARD Medicare models; per the White House, 25 other pharma companies have signed similar agreements with the US government.
• Antitrust settlement quantum not disclosed — CFO Jayashree Satagopan deferred to the annual report, where particulars of the settlement (addressing historical generic pricing litigation exposure) are disclosed.